Peritoneal Dialysis. End stage renal disease
Conditions
Interventions
Intervention 1: Intervention group: Treated with 200 micrograms alpha brand selenium tablets, every afternoon for 3 consecutive months. Intervention 2: Control group: Treated with placebo tablets dail
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Patients undergoing peritoneal dialysis over 18 years of age At least three months have passed since the first dialysis session Satisfied with the study
Exclusion criteria
Exclusion criteria: Having active hepatitis (according to several studies, selenium levels decrease in patients with hepatitis B and C) Normal serum selenium levels Taking steroidal and non-steroidal anti-inflammatory drugs within two months before the start of the study Take selenium supplements within two months of starting the study Insufficient incompatibility to consume the product
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum selenium levels. Timepoint: Before the start and after the end of 3 months. Method of measurement: Serum selenium level of patients by atomic electron normal absorption method with graphite furnace using unicam929-uk device made by variant company in USA.;Lipid profiles (including total cholesterol, LDL, HDL, and TG). Timepoint: Before the start and after the end of 3 months. Method of measurement: By standard laboratory methods.;Indicators associated with anemia. Timepoint: Before the start and after the end of 3 months. Method of measurement: By standard laboratory methods.;Iinflammation. Timepoint: Before the start and after the end of 3 months. Method of measurement: By standard laboratory methods. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShirinsadat Badri
Esfahan University of Medical Sciences
Outcome results
None listed